Denali Therapeutics (DNLI) Q3 FY2025 earnings: revenue $0
Denali Therapeutics Inc. (DNLI) reported revenue of $0 for Q3 FY2025, the quarter ended 30 September 2025. Net income was -$127 million, and diluted earnings per share $-0.74. The figures are the company's own, from the 10-Q it filed with the SEC on 3 November 2026.
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
| $ million | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | On the quarter | On the year | Last 8 quarters |
|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | |||
| Cost of revenue | 0.0 | 0.0 | n/a | |||
| Gross profit | 0.0 | 0.0 | n/a | |||
| Research and development | 102 | 103 | 98.2 | -0.7% | +3.8% | |
| Selling, general and administrative | 35.5 | 32.3 | n/a | +10.0% | ||
| Operating income | -137 | -135 | -123 | |||
| Net income | -127 | -124 | -107 | |||
| Diluted EPS | -$0.74 | -$0.72 | -$0.63 |
$ million except per share.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow
| $ million | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | On the quarter | On the year | Last 8 quarters |
|---|---|---|---|---|---|---|
| Operating cash flow | -107 | -75.3 | -59.1 | |||
| Capital expenditure | n/a | 4.3 | 3.9 | |||
| Free cash flow | n/a | -79.6 | -63.0 | |||
| Cash from investing | 57.8 | 158 | 93.7 | -63.4% | -38.3% | |
| Cash from financing | -0.8 | 1.6 | -18.6 | |||
| Depreciation and amortisation | 2.9 | 3.0 | 1.8 | -3.2% | +60.3% | |
| Share-based compensation | 25.1 | 25.4 | 24.9 | -1.0% | +1.1% | |
| Diluted shares, weighted | 172m | 171m | 169m | +0.6% | +1.7% | |
| Shares outstanding at period end | 147m | 146m | 144m | +0.6% | +1.9% |
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
| $ million | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | On the quarter | On the year | Last 8 quarters |
|---|---|---|---|---|---|---|
| Shareholders' equity | 926 | 1,027 | 1,318 | -9.8% | -29.8% | |
| Debt | 0.0 | 0.0 | 0.0 | |||
| Operating lease liabilities | 29.7 | 32.1 | 38.9 | -7.5% | -23.6% | |
| Finance lease liabilities | 5.6 | 5.6 | 5.6 | -0.4% | -1.4% | |
| Other liabilities | 94.2 | 102 | 91.0 | -7.2% | +3.5% | |
| Total liabilities and equity | 1,056 | 1,166 | 1,454 | -9.5% | -27.4% | |
| Fixed assets | 53.7 | 58.7 | 50.8 | -8.5% | +5.7% | |
| Investments | 782 | 836 | 1,191 | -6.5% | -34.4% | |
| Cash and equivalents | 91.0 | 141 | 90.6 | -35.6% | +0.4% | |
| Other assets | 129 | 130 | 121 | -0.9% | +6.4% | |
| Total assets | 1,056 | 1,166 | 1,454 | -9.5% | -27.4% |
Questions
What was Denali Therapeutics' revenue in Q3 FY2025?
Denali Therapeutics (DNLI) reported revenue of $0 for Q3 FY2025, the quarter ended 30 September 2025.
How much did Denali Therapeutics earn in Q3 FY2025?
Net loss for Q3 FY2025 was $127 million, and the diluted loss per share $0.74.
When did Denali Therapeutics report Q3 FY2025 results?
Denali Therapeutics filed its 10-Q for the quarter ended 30 September 2025 with the SEC on 3 November 2026.
Quarterly results, the last 20 quarters
| Q1 FY2021 | Q2 FY2021 | Q3 FY2021 | Q4 FY2021 * | Q1 FY2022 | Q2 FY2022 | Q3 FY2022 | Q4 FY2022 * | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q2 FY2025 | Q3 FY2025 | Q2 FY2026 | Q3 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.9 | 22.9 | 5.3 | 12.5 | 42.1 | 52.5 | 3.6 | 10.3 | 35.1 | 294 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6 | 17.8 |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.0 | 0.0 | 0.1 | 0.2 |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.0 | 0.0 | 3.5 | 17.6 |
| Gross margin | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 97% | 99% |
| R&D | 60.2 | 65.7 | 71.6 | 67.9 | 86.1 | 92.7 | 87.8 | 92.1 | 129 | 97.5 | 89.7 | 108 | 107 | 91.4 | 98.2 | 99.8 | 103 | 102 | 97.0 | 106 |
| SG&A | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 32.3 | 35.5 | 36.3 | 37.5 |
| Operating income | -71.2 | -61.8 | -85.6 | -77.1 | -66.5 | -61.4 | -107 | -105 | -121 | 170 | -114 | -133 | -118 | -117 | -123 | -130 | -135 | -137 | -131 | -127 |
| Operating margin | -899% | -269% | -1620% | -616% | -158% | -117% | -3020% | -1024% | -344% | 58% | -8981% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -3622% | -713% |
| Net income | -70.0 | -60.7 | -84.6 | -75.3 | -65.2 | -58.8 | -103 | -98.7 | -110 | 183 | -99.4 | -119 | -102 | -99.0 | -107 | -115 | -124 | -127 | -128 | 70.1 |
| Net margin | -884% | -265% | -1601% | -601% | -155% | -112% | -2902% | -960% | -312% | 62% | -7842% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -3539% | 394% |
| Diluted EPS | -$0.58 | -$0.50 | -$0.69 | -$0.62 | -$0.53 | -$0.48 | -$0.84 | -$0.75 | -$0.80 | $1.30 | -$0.72 | -$0.86 | -$0.68 | -$0.59 | -$0.63 | -$0.67 | -$0.72 | -$0.74 | -$0.68 | $0.37 |
| Operating cash flow | -50.2 | -54.2 | -41.4 | -65.5 | -72.1 | -42.9 | -57.0 | -72.7 | -58.8 | -113 | -87.4 | -98.7 | -114 | -91.2 | -59.1 | -83.7 | -75.3 | -107 | -97.0 | -117 |
| Capital expenditure | 2.8 | 0.8 | 1.9 | 3.1 | 4.0 | 2.9 | 6.0 | 4.8 | 2.8 | 5.8 | 2.1 | 2.2 | 2.1 | 4.8 | 3.9 | 5.1 | 4.3 | n/a | 0.8 | 1.0 |
| Free cash flow | -53.0 | -55.0 | -43.3 | -68.5 | -76.2 | -45.8 | -63.1 | -77.5 | -61.6 | -119 | -89.4 | -101 | -116 | -96.0 | -63.0 | -88.8 | -79.6 | n/a | -97.8 | -118 |
| Shares outstanding | 121m | 122m | 122m | 122m | 123m | 123m | 124m | 136m | 137m | 137m | 138m | 138m | 143m | 143m | 144m | 144m | 146m | 147m | 160m | 160m |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.10-Q for the period ended 30 September 2025, filed 3 November 2026: the filing.